Omega Fund, including Director Stampacchia, invests $2.5M in ImageneBio PIPE
IMA sits 51% above its 52-week low of $3.94 on light trading volume (0.1× avg).
Summary
Omega Fund, a major institutional investor and a director, invested $2.5 million in ImageneBio's recent $30 million private placement, increasing their stake to 8.4%.
Key Events · Ownership and Investor Activity · IMA
-
Significant Investment in PIPE
Omega Fund, a major institutional investor, acquired pre-funded warrants worth approximately $2.5 million in ImageneBio's recent $30 million private placement.
-
Increased Ownership Stake
This investment, combined with existing holdings, brings Omega Fund's beneficial ownership to 8.4% of ImageneBio's common stock.
-
Director Involvement
Otello Stampacchia, a director of ImageneBio, is part of the reporting group, signaling insider confidence in the financing.
-
Context of Capital Raise
This filing provides specific details of a key investor's participation in the $30 million private placement announced on April 13, 2026, which is crucial for the company's financial runway.
Analysis · IMA · Life Sciences
This Schedule 13D filing reveals that Omega Fund, a significant institutional investor with a board representative (Otello Stampacchia), acquired approximately $2.5 million in pre-funded warrants as part of ImageneBio's recently announced $30 million private placement. This substantial investment, representing 3.77% of the company's market capitalization, increases Omega Fund's beneficial ownership to 8.4%. The participation of a major institutional investor and a director in this capital raise provides a strong signal of confidence in the company's future, particularly as it secures crucial funding for its operations and clinical development, following the positive Phase 1b/2a clinical results for IMG-007.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMA was trading at $5.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.3M. The 52-week trading range was $3.94 to $216.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.